Empiric Vancomycin Use After Prior MRSA Culture With Subsequent Negative Cultures
Empiric MRSA-active therapy (eg, vancomycin) is recommended when suspected infection severity and host risk factors indicate substantial risk for MRSA, including a history of prior MRSA infection or nasal colonization. [1]
Current admission cultures that do not isolate MRSA should trigger prompt reassessment for de-escalation once culture data are available and MRSA is not demonstrated. NIH OI CAP guideline
Medication Selection Algorithm
Empiric MRSA coverage (vancomycin, linezolid, daptomycin, or ceftaroline for MRSA-directed therapy) is recommended when all of the following apply. [1]
- Suspected SSTI is severe, in a hospitalized patient, or otherwise meets criteria for MRSA coverage. [1]
- Prior MRSA infection or MRSA colonization history is present. [1]
- Coverage is needed pending culture and Gram-stain results. [1]
Core Recommendation: Prior MRSA Infection as a Continuing Risk Factor
For hospitalized SSTI management, a prior MRSA infection or nasal colonization is an explicit reason to include MRSA-active therapy in the initial empiric regimen. [1]
Monotherapy vs Combination Therapy
When MRSA-active therapy is indicated for polymicrobial SSTI concerns, MRSA agents (eg, vancomycin) are combined with additional gram-negative and anaerobic coverage. [1]
When a culture-supported monomicrobial gram-positive process is demonstrated, broad empiric combinations should be narrowed to the least-spectrum effective regimen. NIH OI CAP guideline
Treatment Initiation Thresholds
Empiric MRSA-active therapy should be initiated promptly in hospitalized patients with suspected SSTI when prior MRSA infection or nasal colonization is present, even if current admission cultures have not yet resulted. [1]
De-escalation When Current Cultures Remain MRSA-Negative
MRSA-targeted therapy should be de-escalated when culture results do not support MRSA infection. NIH OI CAP guideline
Clinical de-escalation strategies for empiric vancomycin have been studied in respiratory infections using negative MRSA nasal/throat testing to support discontinuation when MRSA is not demonstrated. A Trial of Discontinuation of Empiric Vancomycin Therapy in Suspected MRSA HCAP
Common Pitfalls to Avoid
Persisting with vancomycin after MRSA is not demonstrated delays spectrum narrowing and increases antibiotic exposure without microbiologic support. NIH OI CAP guideline
Target Goals of Therapy
The goal of empiric MRSA coverage is prevention of undertreatment during the culture pending interval for patients at elevated MRSA risk. [1]
The goal after cultures return MRSA-negative is rapid narrowing or discontinuation of MRSA-directed therapy when MRSA infection is no longer supported. NIH OI CAP guideline